4.8 Article

Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax

Journal

FRONTIERS IN IMMUNOLOGY
Volume 6, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2015.00348

Keywords

malaria; vaccine; Plasmodium vivax; blood-stage; adenovirus; poxvirus; MVA; Duffy-binding protein

Categories

Funding

  1. EMV DA (European Malaria Vaccine Development Association, a European Commission (EC)) [LSHP-CT-2007-0375061]
  2. MRC Clinical Training Fellowship [G0600424]
  3. Rhodes Trust - Wellcome Trust [084113/7/07/Z]
  4. UK Medical Research Council (MRC) [G1100086]
  5. European Community [242095 - EVIMalaR]
  6. Singapore National Medical Research Council [NMRC/CBRG/0047/2013]
  7. Singapore Immunology Network (SIgN)
  8. horizontal Program on Infectious Diseases under the Agency for Science, Technology and Research (A*STAR, Singapore)
  9. Wellcome Trust of Great Britain, as part of the Oxford Tropical Medicine Research Program of Wellcome Trust-Mahidol University
  10. Singapore International Graduate Award (SINGA)
  11. Malaria Vaccine Initiative (MVI)
  12. PAIN
  13. Department of Biotechnology (DRT), Government of India (GoI)
  14. TATA Innovation Fellowship of DBT, GoI - UK MRC
  15. UK Department for International Development (DFID)
  16. MRC [G1100086, G1000527, G0600424] Funding Source: UKRI
  17. Medical Research Council [G1100086, G0600424, G1000527] Funding Source: researchfish

Ask authors/readers for more resources

Malaria vaccine development has largely focused on Plasmodium falciparum; however, a reawakening to the importance of Plasmodium vivax has spurred efforts to develop vaccines against this difficult to treat and at times severe form of relapsing malaria, which constitutes a significant proportion of human malaria cases worldwide. The almost complete dependence of P. vivax red blood cell invasion on the interaction of the P vivax Duffy-binding protein region II (PvDBP_RII) with the human Duffy antigen receptor for chemokines (DARC) makes this antigen an attractive vaccine candidate against blood stage P vivax. Here, we generated both preclinical and clinically compatible adenoviral and poxviral vectored vaccine candidates expressing the Salvador I allele of PvDBP_RII- including human adenovirus serotype 5 (HAdV5), chimpanzee adenovirus serotype 63 (ChAd63), and modified vaccinia virus Ankara (MVA) vectors. We report on the antibody and T cell immunogenicity of these vaccines in mice or rabbits, either used alone in a viral vectored prime-boost regime or in mixed-modality adenovirus prime proteinin-adjuvant boost regimes (using a recombinant PvDBP_RII protein antigen formulated in Montanide (R) ISA720 or Abisco (R) 100 adjuvants). Antibodies induced by these regimes were found to bind to native parasite antigen from P. vivax infected Thai patients and were capable of inhibiting the binding of PyDBP_RII to its receptor DARC using an in vitro binding inhibition assay. In recent years, recombinant ChAd63 and MVA vectors have been quickly translated into human clinical trials for numerous antigens from F? falciparum as well as a growing number of other pathogens. The vectors reported here are immunogenic in small animals, elicit antibodies against PvDBP_RII, and have recently entered clinical trials, which will provide the first assessment of the safety and immunogenicity of the PyDBP_RII antigen in humans.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available